University Hospital
Banī Suwayf, Beni Suweif Governorate, 13556, Egypt
Completed
NCT Number: NCT05689229
Aerosolized Versus Intravenous Colistin-based Antimicrobial Regimens in Hospitalized COVID-19 Patients With Bacterial Coinfection: A Randomized Controlled Trial
Secondary bacterial pathogen infection has been demonstrated to aggravate COVID-19 clinical outcomes. Bacterial infections acquired during a hospital stay are likely resistant to several antimicrobial medicines, making COVID-19 patient management difficult. As a result, it is believed that aerosolized colistin might be a viable choice for treating secondary bacterial infections caused by gram-negative resistant strains in individuals who also have COVID-19 infection.
Completed
Looking for future studies?
Notify MeKey information
Age range
18 year–70 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Covid-19 patients with secondary gram-negative bacterial infections
Exclusion criteria
- Patients with resistant bacterial strains to polymyxins
- patients less than 18 years
Treatment and study plan
Colistin
DrugCOVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized
Primary outcomes
-
Microbial eradication
Time frame: 10 days
-
Mortality
Time frame: 30 days
Secondary outcomes
-
Nephrotoxicity
Time frame: 10 days
Sponsors and collaborators
Lead sponsor
Beni-Suef University
Other
Registry information
Acronym: colistin
Important dates
- Study start
- 2021
- Primary completion
- 2021
- Study completion
- 2021
- First posted
- Jan 19, 2023
- Registry last updated
- Jan 19, 2023
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.